1239685-39-2

Upstream product

• 24827-37-0 N-(4-chlorobenzyl)thiourea 
• 27738-96-1 chlorocarbonyl isocyanate 
• 74-88-4 methyl iodide 

Downstream Products

• 1239691-18-9 1-(4-chlorobenzyl)-3-(methoxycarbonylmethyl)-6-(methylthio)-1,3,5-triazine-2,4(1H,3H)-dion 
• 1239691-16-7 1-(4-chlorobenzyl)-6-(methylthio)-3-(2-((tetrahydro-2H-pyran-2-yl)oxy)ethyl)-1,3,5-triazine-2,4(1H,3H)-dione 
• 1239685-41-6 1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylamino)-3-(2-pyridylmethyl)-1,3,5-triazine-2,4(1H,3H)-dion 
• 1239685-42-7 1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylamino)-3-(2-hydroxyethyl)-1,3,5-triazine-2,4(1H,3H)-dion 
• 1239685-46-1 1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylamino)-3-(hydroxycarbonylmethyl)-1,3,5-triazine-2,4(1H,3H)-dion 
• 1239685-45-0 1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylamino)-3-(methoxycarbonylmethyl)-1,3,5-triazine-2,4(1H,3H)-dion 
• 1239685-47-2 1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylamino)-3-(methylcarbamoylmethyl)-1,3,5-triazine-2,4(1H,3H)-dion 
• 1239685-48-3 4-chloro-1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylamino)-1,3,5-triazine-2(1H)-one 
• 1239685-49-4 1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylamino)-4-(2-hydroxyethoxy)-1,3,5-triazine-2(1H)-one 
• 1239691-19-0 1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylamino)-4-(2-(tetrahydro-2H-pyrane-2-yloxy)ethoxy)-1,3,5-triazine-2(1H)-one 
• 1239685-50-7 4-benzylamino-1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylamino)-1,3,5-triazine-2(1H)-one 
• 1239685-51-8 1-(4-chlorobenzyl)-4-(dodecylthio)-6-(3-fluoro-4-isopropoxyphenylamino)-1,3,5-triazine-2(1H)-one 
• 1239689-27-0 methyl 3-(3-(4-chlorobenzyl)-4-(methylthio)-2,6-dioxo-3,6-dihydro-1,3,5-triazin-1(2H)-yl)-2,2-dimethylpropanoate 
• 1239685-40-5 1-(4-chlorobenzyl)-6-(3-fluoro-4-isopropoxyphenylamino)-1,3,5-triazine-2,4(1H,3H)-dion 

Relevant academic research and scientific papers

Dioxotriazine derivatives as a new class of P2X3 receptor antagonists: Identification of a lead and initial SAR studies

P2X3 receptor is an ATP-gated ion channel, mainly localized on peripheral sensory neurons. Currently, several clinical trials are being conducted with P2X3 receptor antagonists for the treatment of chronic pain or cough. To identify

NOVEL TRIAZINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME

The present invention provides a novel P2X3 and/or P2X2/3 receptor antago nist. A compound represented by the formula (I): wherein Ra, Rb and Rc are, (a) Ra and Rb are taken together =Z; and Rc is a group represented by R1c; or (b) Rb and Rc are taken together to form a bond; and Ra is a group represented by -Y-R1a; R1a and R1c are each independently hydrogen, substituted or unsubstituted alkyl, etc.; R2 and R3 are each independently substituted or unsubstituted aryl, etc.; R4a and R4b are each independently hydrogen, substituted or unsubstituted alkyl, etc.; X is -N(R5)-, etc.; R5 is hydrogen, substituted or unsubstituted lower alkyl, etc.; -Y- is -O-, etc.; =Z is =O, etc.; and n is an integer of 0 to 4.